Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco "YOURxPLAN" Preferred List Includes 13 Schering Drugs, Cenestin

Executive Summary

The Merck-Medco/Reader's Digest "YOURxPLAN" prescription discount service includes 13 Schering-Plough drugs on its list of "select" products that generate cash refunds to enrollees.

You may also be interested in...



Who's Afraid Of Patent Losses? Merck, Schering, BMS Defenses Play Well

Merck has regenerating brands; Schering-Plough has desloratadine; Bristol-Myers Squibb has an 11th-hour patent and a combo replacement for a major single-ingredient expiration; and they all have recession-haven reputations.

Who's Afraid Of Patent Losses? Merck, Schering, BMS Defenses Play Well

Merck has regenerating brands; Schering-Plough has desloratadine; Bristol-Myers Squibb has an 11th-hour patent and a combo replacement for a major single-ingredient expiration; and they all have recession-haven reputations.

Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms

Merck is edging away from its strict go-it-alone policy and sidling up a little closer to Schering-Plough in a series of deals - the most recent of which is a co-promotion agreement with Schering-Plough for the Phase III cholesterol absorption inhibitor ezetimibe.

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel